CN203341802U - Induction-type uterine cavity delay release system - Google Patents
Induction-type uterine cavity delay release system Download PDFInfo
- Publication number
- CN203341802U CN203341802U CN 201320366574 CN201320366574U CN203341802U CN 203341802 U CN203341802 U CN 203341802U CN 201320366574 CN201320366574 CN 201320366574 CN 201320366574 U CN201320366574 U CN 201320366574U CN 203341802 U CN203341802 U CN 203341802U
- Authority
- CN
- China
- Prior art keywords
- delay release
- uterine
- uterine cavity
- charge valve
- resilient bladder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
Images
Abstract
The utility model discloses an induction-type uterine cavity delay release system. After an inducted abortion operation, the occurrence rate of intrauterine adhesion is high, after an intrauterine adhesion operation, the situation of re-adhesion is serious, and no good solution exists at present. The induction-type uterine cavity delay release system comprises a uterine-shaped elastic ball bag support, a delay release drug film, a catheter and a one-way inflation valve. The uterine-shaped elastic ball bag support is a hollow isosceles triangle structure body, the bevel edges of an isosceles triangle are respectively 3.5 cm, and the bottom edge of the isosceles triangle is 3cm. One end of the catheter is connected and communicated with the vertex angle end of the uterine-shaped elastic ball bag support, the other end of the catheter is connected with the one-way inflation valve, and a plurality of annular scales are arranged on the outer side of the end, close to the uterine-shaped elastic ball bag support, of the catheter. The one-way inflation valve comprises an inflation valve body and a pressure sensor. The delay release drug film wraps the outer portion of the uterine-shaped elastic ball bag support, and the delay release drug film is made of fiber albumen glue which contains delay release drug. The induction-type uterine cavity delay release system is simple in structure, easy to operate, not prone to injuring the uterine cavity and capable of effectively preventing intrauterine adhesion.
Description
Technical field
This utility model belongs to medical instruments field, relate to a kind of Irritability uterine cavity slow-released system, for placing after the various intrauterine surgicals such as artificial abortion, intrauterine adhesion exclusion or excision, uterus vertical phrenectomy, transcervical resection of polyp and uterine malformation anaplasty.
Background technology
Along with the change of life style and the impact of climate, increasing women lived through once even repeatedly unexpected gestation before fertility.Artificial abortion, as the current most widely used method that stops unexpected gestation clinically, is generally accepted by whole world women.According to World Health Organization (WHO), estimate, the whole world has ten thousand miscarriages of 2500-5500 to occur every year, and the related number of artificial abortion is many, scope is wide, has become global social problem and important public health problem.According to statistics, China has 1,000 ten thousand routine artificial abortion every year on average, and repeat abortion (referring to that medicine stream or artificial abortion number of times add up to >=2 times) phenomenon is more serious, especially in the repeat abortion person, nullipara's ratio increases year by year, calendar year 2001 whole nation family planning healthy reproduction investigation and analysis report is pointed out, in the women of 20-25 between year, 3/4 for not educating, but repetitive stream productive rate (32.4 ﹪) is with married to have educated the women close.Artificial abortion is divided into drug induced abortion and Surgical abortion, although comparatively safe reliable, but also can produce various untoward reaction and complication, which kind of Abortion methods all inevitably can cause endometrial impairment, bring out hemorrhage, infection, endometritis, chronic pelvic inflammatory disease, intrauterine is lepthymenia etc., severe patient causes intrauterine adhesion.
Intrauterine adhesion (intrauterine adhesion, IUA), often be secondary to invasive surgery history in uterine cavity, is also a kind of complication common after artificial abortion.Endometrium is divided into 3 layers of compacted zone, spongy layer and basal layeres.Intimal surface 2/3 is compacted zone and spongy layer general designation functional layer, is subject to ovarian sex hormone to affect generating period and changes and come off, and forms menstruation.Basal layer is near myometrial 1/3 inner membrance, not affected by ovarian sex hormone, not the variation of generating period.When various artificial abortion, the basal layer caused as Surgical abortion, drug induced abortion, spontaneous abortion and the clearing heat in the pericardium damages or comes off, cicatrization after endometrium infects, Uterus wall is adhered mutually, form adhesion, then uterine cavity distortion, cause endometrium refractoriness or obstructive amenorrhea, be that infertility is modal clinically at present is also the most thorny cause of disease.According to domestic and foreign literature, the IUA sickness rate is ascendant trend year by year in recent years.After in January, 1991 to 2000 year December Therapeutic Abortion, the IUA incidence rate is 0.4 ﹪, and be 0.6 ﹪ year March January to 2007 calendar year 2001, in recent years report Therapeutic Abortion after the IUA prevalence up to 37.6 ﹪.The 56-90 ﹪ that repeatedly post-abortion, the IUA incidence rate reached total IUA incidence rate does not wait.Body and mind to the women all causes greatly damage, directly affects later fertility, even affects the stable of family and society.
To the IUA standard treatments, be the descending intrauterine adhesion exclusion of direct-view of hysteroscope or excision clinically at present, no matter use mechanicalness partition method or electroresection, laser fiber excision method, all easily again stick together, bibliographical information IUA Postoperative recurrent rate is up to 23.5 ﹪, wherein 20.0-62.5 ﹪ is severe adhesion, and indivedual patients may need repeat surgery 5-6 time.Therefore preventing its generation and recurrence is the key that treatment is successful.Have the scholar to advocate postoperative placement of intrauterine devices, every day, three oral progynova 1-3mg, occurred to prevent adhesion again.But intrauterine device is flat ring-type or T shape, can't supports the uterine cavity of pyriform fully, and can not effectively prevent the position the most easily sticked together--the formation of palace Goniosynechiae.In utero support zone is point-like or streak, therefore birth control apparatus easily occurs and enter endometrium or myometrium, and birth control apparatus incarceration and implantation occur.Progynova is estrogen, evidence suggests that heavy dose of oral estrogen can increase the women and suffer from the estrogen-dependent tumor, as the onset risk of hysteromyoma, breast carcinoma, ovarian cancer.And not only excessive estrogen can not promote endometrial growth, and inhibitory action is appearred in hypothalamus and hypophysis, suppress on the contrary endometrial growth, occur that intrauterine is lepthymenia, hypomenorrhea is amenorrhea even, can't effectively prevent the generation of IUA.IUA is the modal reason of uterus barrenness, and therapeutic effect is undesirable, the women the is lost chance bred.And the current replace-conceive of China is still illegal, so the fertility Issue that IUA causes becomes the difficulty that can't capture.
Summary of the invention
The purpose of this utility model is the blank for prior art, and a kind of Irritability uterine cavity slow-released system is provided.
This utility model Irritability uterine cavity slow-released system comprises palace shape resilient bladder support, slow-release medicine-membrane, conduit, unidirectional charge valve; The isosceles triangular structure body that described palace shape resilient bladder support is hollow, the waist of this isoceles triangle shape is 3.5cm, base is 3cm; One end of conduit is connected and connects with palace shape resilient bladder support drift angle end, for the gas replenishment process air, from conduit, enter in the shape resilient bladder support of palace, the other end of conduit is connected with unidirectional charge valve, conduit is provided with a plurality of circular scales near an end lateral surface of palace shape resilient bladder support, the distance of the first circular scale and palace shape resilient bladder support drift angle is 1cm, and the distance of adjacent two circular scales is 1cm; Described unidirectional charge valve comprises charge valve, pressure transducer, described pressure transducer is located at the end that unidirectional charge valve is connected with conduit, for the pressure of perception palace shape resilient bladder support, described charge valve is located at the other end of unidirectional charge valve, for inflating and avoid gas leakage.
The material of described palace shape resilient bladder support is the hollow medical grade silicon rubber;
Described palace shape resilient bladder support is coated with slow-release medicine-membrane, and the material of this slow-release medicine-membrane is Fibrin Glue, includes the antibiotic medicines such as epidermal growth factor, estrogen, chitosan and gentamycin;
This device enters air in the shape resilient bladder support of palace by conduit by charge valve, make palace shape resilient bladder support expand, pressure transducer perception palace shape resilient bladder poppet pressure, make palace shape resilient bladder support and uterine cavity laminating, if, and the pressure of pressure transducer perception is less than 24KPa and can be inflated, if be greater than 24KPa, stop immediately pouring into air.
The beneficial effects of the utility model are:
1. comply with the uterine cavity shape after the inflation of this utility model device, the slow-release medicine-membrane of palace shape resilient bladder support periphery covers the uterine cavity wound surface fully, and the palace dihedral is become effectively to support, and effectively prevents the generation of uterine cavity and the adhesion of bight, palace thereof.
2. this utility model device, owing to having increased slow-release medicine-membrane, has been avoided the effect of the simple support of common uterine cavity support, has avoided heavy dose of repeat administration and the antibiotic repetition intravenous drip of oral estrogen.And this utility model make medicine all in uterus film directly absorb, do not need blood that medicine is carried into to this zone, avoided the shortcoming of systemic administration, reduced Liver and kidney and the infringement of removing the whole body other organs, increased the local action effect of medicine, reduce drug use dosage, reduce the burden of patient's economy, the generation of adhesion again after the generation of minimizing IUA and intrauterine adhesion exclusion.
3. the slow-release medicine-membrane of palace shape resilient bladder support periphery be take Fibrin Glue as carrier.Fibrin Glue simulation human body self blood coagulation reaction final stage is formed has stable three dimensional structure, larger specific surface area is provided, can carry more medicine, its mesh gap makes medicine by the constant release of given pace, as the carrier of following medicine, make drug absorption for up to about 2 weeks, the enough local support time of medicine is provided, make proper interior drug level remain constant, reduce the toxic and side effects of medicine; And good biocompatibility can absorb fully voluntarily:
A. micronized 17 β estradiol of estrogen: 1mg, identical with the natural estrogen of human body ovarian secretion, vagina administration active drug concentration is 20 times of estradiol valerate, can promote endometrial ramp and recovery, remain endometrial complete, reduce factor Endometrium basal layer impaired and cause exposed, the protection myometrial tissue; Simultaneously can change the cervical mucus character, make that cervical mucus tails off, thickness, can stop antibacterial up, prevent bacterial invasion, the prevention pelvic infection, prevent the generation of IUA.
B. chitosan: 2ml medical chitose; it is the macromolecular compound chitin of being purified by shrimp and crab shells; a kind of poly-glucosamine of making after deep processing again through deacetylation; there is good biocompatibility, biodegradability and biologic activity; can be suppressed to the fibrocyte hyper-proliferative; accelerate the growth of epithelial cell, endotheliocyte, accelerate the recovery of tissue, reduce the formation of adhesion.Medical chitose has the bacteriostasis of wide spectrum, especially stronger to the gram positive bacteria bacteriostasis, and postoperative uterine cavity is infected certain preventive effect is arranged, and has reduced infective agent and has caused tissue adhesion's possibility.Chitosan is to have certain stickiness, very lubricated spawn, and lubricated and biological barrier, biodegradation are arranged, and at tissue surface, can form uniform protecting film, plays the physical isolation effect, and can the form metabolism with carbon dioxide and water in 2-3 week.Medical chitose can produce coagulation and realize hemostasis cell with the interaction by between itself and erythrocyte, experimental results show that and can effectively reduce the IUA incidence rate.
C. epidermal growth factor (EGF) is a kind of 53 amino acid whose single chain polypeptide class materials that contain, epithelial cell to the Various Tissues source has very strong Mitogenic activity, studies confirm that, in endometrial various cells of each phase, expression is arranged, autocrine and paracrine factor for endometrial cell growth and differentiation adjusting, propagation to endometrial glandular epithelial cells and Interstitial cell all has stimulation, and EGF all can stimulate the growth of endometrial glandular epithelial cells and Interstitial cell in vivo and in vitro, reduce IUA and the lepthymenia generation of intrauterine.
D. antibiotic is as the gentamycin local sustained release, and low dose can reach active drug concentration in uterine cavity, and it is constant to maintain drug level, in the time of effective prevention infection, avoid the toxic and side effects of systemic administration, reduce the generation of endometritis, prevent the generation of IUA.
4. but palace type sacculus medial wall pressure transducer perception balloon pressure, 24KPa is that the intermediate value to the uterine rupture critical pressure appears in pain, adjust pressure according to individual variation and make it to be less than 24KPa, prevent that hypertonia from causing the endometrium necrosis, hypotony causes slow-released system to come off.
The accompanying drawing explanation
The structural representation that Fig. 1 is this utility model device.
The specific embodiment
Below in conjunction with accompanying drawing, this utility model is further analyzed.
This utility model Irritability uterine cavity slow-released system comprises palace shape resilient bladder support 1, slow-release medicine-membrane 2, conduit 3, unidirectional charge valve 4; The isosceles triangular structure body that described palace shape resilient bladder support 1 is hollow, the waist of this isoceles triangle shape is 3.5cm, base is 3cm; One end of conduit 3 is connected and connects with palace shape resilient bladder support 1 drift angle end, conduit is provided with a plurality of circular scales 5 near an end lateral surface of palace shape resilient bladder support 1, the distance of the first circular scale 5-1 and palace shape resilient bladder support 1 drift angle is 1cm, and the distance of adjacent two circular scales 5 is 1cm; Described unidirectional charge valve 4 comprises charge valve, pressure transducer, described pressure transducer is located at the end that unidirectional charge valve 4 is connected with conduit 3, for the pressure of perception palace shape resilient bladder support 1, described charge valve is located at the other end of unidirectional charge valve 4, for inflating and avoid gas leakage.
The material of described palace shape resilient bladder support 1 is the hollow medical grade silicon rubber;
Described palace shape resilient bladder support 1 is coated with slow-release medicine-membrane 2, and the material of this slow-release medicine-membrane 2 is Fibrin Glue, includes the antibiotic medicines such as epidermal growth factor, estrogen, chitosan and gentamycin;
This device enters air in palace shape resilient bladder support 1 through charge valve 5 by conduit 3, make palace shape resilient bladder support 1 expand, pressure transducer perception palace shape resilient bladder support 1 pressure, make palace shape resilient bladder support 1 and uterine cavity laminating, and the pressure of pressure transducer perception is less than 24KPa and can be inflated, if be greater than 24KPa, stop pouring into air.
Work process:
After artificial abortion or after intrauterine adhesion exclusion or excision, through cervix uteri, this utility model Irritability uterine cavity slow-released system is inserted to uterine cavity, conduit 3 is stayed intravaginal, then by unidirectional charge valve 4, is inflated, and according to pressure transducer, adjusts the injected gas scale of construction.But according to the lower incremental expansion uterine cavity of clinical needs pressure sensing monitoring.Within two weeks, by the emptying palace of charge valve shape resilient bladder support 1 interior air, by vagina, take out.
Above-described embodiment is not that this utility model is not limited only to above-described embodiment for restriction of the present utility model, as long as meet this utility model requirement, all belongs to protection domain of the present utility model.
Claims (1)
1. Irritability uterine cavity slow-released system, is characterized in that this system comprises palace shape resilient bladder support, slow-release medicine-membrane, conduit, unidirectional charge valve; The isosceles triangular structure body that described palace shape resilient bladder support is hollow, the waist of this isoceles triangle shape is 3.5cm, base is 3cm; One end of conduit is connected and connects with palace shape resilient bladder support drift angle end, the other end of conduit is connected with unidirectional charge valve, conduit is provided with a plurality of circular scales near an end lateral surface of palace shape resilient bladder support, the distance of the first circular scale and palace shape resilient bladder support drift angle is 1cm, and the distance of adjacent two circular scales is 1cm; Described unidirectional charge valve comprises charge valve, pressure transducer, and pressure transducer is located at the end that unidirectional charge valve is connected with conduit, and charge valve is located at the other end of unidirectional charge valve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201320366574 CN203341802U (en) | 2013-06-25 | 2013-06-25 | Induction-type uterine cavity delay release system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201320366574 CN203341802U (en) | 2013-06-25 | 2013-06-25 | Induction-type uterine cavity delay release system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203341802U true CN203341802U (en) | 2013-12-18 |
Family
ID=49741751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201320366574 Withdrawn - After Issue CN203341802U (en) | 2013-06-25 | 2013-06-25 | Induction-type uterine cavity delay release system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203341802U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301558A (en) * | 2013-06-25 | 2013-09-18 | 杭州安体科技有限公司 | Inductive uterine slow release system |
| CN105078642A (en) * | 2014-05-14 | 2015-11-25 | 饶永 | Implant for uteruses |
-
2013
- 2013-06-25 CN CN 201320366574 patent/CN203341802U/en not_active Withdrawn - After Issue
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103301558A (en) * | 2013-06-25 | 2013-09-18 | 杭州安体科技有限公司 | Inductive uterine slow release system |
| CN105078642A (en) * | 2014-05-14 | 2015-11-25 | 饶永 | Implant for uteruses |
| CN105078642B (en) * | 2014-05-14 | 2018-07-24 | 吴江永元生物科技有限公司 | A kind of uterus implant |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103301558B (en) | Inductive uterine slow release system | |
| CN103784244B (en) | A kind of intrauterine implant | |
| Narducci et al. | Vacuum-assisted closure therapy in the management of patients undergoing vulvectomy | |
| CN109925539A (en) | A kind of elastic membrane, preparation method and application | |
| RU2582226C1 (en) | Method for treatment and prevention of recurrent intrauterine adhesions | |
| Inal et al. | Comparison of vaginal misoprostol and dinoprostone for cervical ripening before diagnostic hysteroscopy in nulliparous women | |
| Sterling et al. | Lesions of urachus which appear in the adult | |
| CN105078642A (en) | Implant for uteruses | |
| CN103637836A (en) | Intrauterine adhesion prevention and treatment device | |
| Sengul et al. | Incisional endometriosis: a report of 3 cases | |
| CN203341802U (en) | Induction-type uterine cavity delay release system | |
| De Lee et al. | The Year Book of Obstetrics and Gynecology... | |
| RU2525533C1 (en) | Method of treatment and prevention of recurrences of intrauterine synechiae | |
| Prince et al. | Endometriosis of the perineum: review of the literature and case report | |
| Zhou et al. | Laparoscopic–Assisted Uterovaginal Anastomosis for Uterine Cervix Atresia With Vaginal Aplasia Using a Silicone Stent Lined With Acellular Porcine Small Intestinal Submucosa Graft Inserted Using a 16F Foley Catheter | |
| Gupta et al. | Non-oral routes, novel formulations and devices of contraceptives: An update | |
| Celik et al. | Total laparoscopic hysterectomy compared with abdominal hysterectomy; clinical outcomes | |
| RU2541089C1 (en) | Method for integrated treatment of external genital endometriosis | |
| Urbán-Morlán et al. | New developments in intrauterine drug delivery systems and devices | |
| RU2436532C1 (en) | Method of preparing immature or insufficiently mature neck of uterus for labour in case of full-term pregnancy, complicated by preterm discharge of light amnioyic fluid | |
| RU2802504C1 (en) | Method of hematocolpos treatment with aplasia of the lower and middle third of the vagina and prevention of its recurrence | |
| Luk et al. | The superinfection of a dermoid cyst | |
| CN107213453A (en) | A kind of abortifacient | |
| Stubblefield | Laminaria and other adjunctive methods | |
| Majoko et al. | Labor induction with vaginal misoprostol and extra-amniotic prostaglandin F2α gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| AV01 | Patent right actively abandoned |
Granted publication date: 20131218 Effective date of abandoning: 20141112 |
|
| RGAV | Abandon patent right to avoid regrant |